Trial Profile
"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype, an International Phase II/Phase III, Randomized, Controlled Trial - TREAT-HAP Study.
Status:
Not yet recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Nosocomial pneumonia
- Focus Adverse reactions; Therapeutic Use
- Acronyms TREAT-HAP
- 26 Jun 2023 New trial record